Summary In phase I studies. lobaplatin showed activity in ovarian cancer patients pretreated with platinum. A phase II trial with lobaplatin was performed in patients with refractory or relapsed ovarian cancer to define activity and pharmacokinetics. Twenty-two patients were treated with lobaplatin administered as an intravenous bolus every 4 weeks. Dependent on creatinine clearance (CRCL) patients received 30 or 50 mgm-2 lobaplatin as the starting dose. Twenty-two patients received 78 courses (median 3, range 1-6). In eight patients total platinum (TPt) in plasma and urine, free platinum (FPt) in plasma ultrafiltrate (both measured by atomic absorption spectrometry) and lobaplatin in plasma ultrafiltrate measured (by high-performance liquid chromatography) were measured. Toxicity was confined to mild nausea and vomiting, mild leucocytopenia (WHO grade 3 in 18% of the courses), and renal function-related thrombocytopenia (WHO grade 3 4 in 53% of the courses). A correlation was found between CRCL and reduction in platelet count (r = -0.77; P<0.0l). No renal toxicity was encountered. Five of 21 evaluable patients (24%) achieved a response (four complete remissions and one partial remission). Remissions occurred mainly in patients who relapsed more than 6 months after primary treatment. The median survival from start of lobaplatin treatment was 8 months. The mean areas under the curve (AUCs) were 4.2 ± 0.5, 3.0 ± 0.6. and 3.2 ± 1.1 h mgl-' for TPt, FPt and lobaplatin respectively. The free platinum fraction (FPt TPt) was initially very high, indicating low protein binding. FPt was essentially present as intact lobaplatin. Four hours after infusion 54 ± 5% and 24 h after infusion 74 ± 3% of the lobaplatin dose was excreted in the urine. In conclusion. lobaplatin is a platinum compound with anti-tumour activity in patients with relapsed ovarian cancer, especially in those who have platinum-sensitive tumours. The main toxicity of lobaplatin is thrombocytopenia and its dose should be corrected according to renal function.
Over the last decade, treatment of patients with ovarian cancer has been dominated by cisplatin-containing regimens (Neijt et al., 1984; Williams et al., 1985; Omura et al., 1986) . Combinations of cisplatin with one single alkylating agent give equivalent results to three-or four-drug schedules, but appear to be less toxic (Neijt et al., 1987) . In recent years, the development of new drugs has been directed towards the development of platinum analogues that are equipotent but less toxic than the parent compound. Carboplatin has emerged as leading analogue in this respe-t with reduced nephrotoxicity, gastointestinal toxicity and neurotoxicity (Calvert et al., 1982; Evans et al., 1983) . Myelotoxicity, especially thrombocytopenia. has been found to be the doselimiting toxicity of carboplatin. Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin (Alberts et al., 1992; Swenerton et al., 1992 ).
An important direction in current research is to find new cisplatin analogues that are less toxic and more effective than second-generation analogues such as carboplatin. One of these compounds might be lobaplatin (1,2-diamminomethylcyclobutane-platinum (II)-lactate, D-19466) (Figure 1 ). Lobaplatin has a greater anti-tumour effect in vitro towards B16 melanoma and AH13s hepatoma than cisplatin (Voegeli et al., 1990) . This was also implied by experiments performed in two cell lines and their cisplatin-resistant sublines. In a small-cell lung carcinoma cell line (GLC4) and its resistant subline (GLC4-CDDP), lobaplatin showed full crossresistance, whereas in another line, a human embryonal cancer cell line (Ntera2/DI), and its cisplatin-resistant subline (tera-CP), lobaplatin demonstrated no cross-resistance (Meijer et al., 1992) . In vivo, in mice bearing P388 leukaemia, administration of lobaplatin resulted in a greater increase in lifespan than cisplatin or carboplatin. In a cisplatin-resistant P388 tumour in which neither cisplatin nor carboplatin was able to inhibit the proliferation after transplantation, the survival of the animals was significantly prolonged by lobaplatin (Voegeli et al., 1990) . These preclinical in vitro and animal data suggest that the anti-tumour activity of lobaplatin is different from that of cisplatin and carboplatin and might be not cross-resistant.
In phase I studies with lobaplatin administered by different schedules (daily bolus infusion for 5 days, 72h continues infusion and single bolus infusion) its main toxicity appeared to be on the bone marrow, and especially concerned thrombocytopenia (Fiebig et al., 1991; Gietema et al., 1993a,b) . Gastrointestinal toxicity was mild and renal toxicity did not occur. In the daily bolus infusion for 5 days schedule the thrombocytopenia was clearly related with the renal function of the individual patients, resulting in different maximal tolerated dosages for different renal function cohorts (Gietema et al., 1993a) . In a one day bolus and a continuous infusion schedule the toxicity pattern was similar to that of a 5 day regimen. The optimal dosages of lobaplatin in the three outlined schedules for patients with a creatinine clearance In phase I studies with lobaplatin tumour responses were seen in several patients with (partial) platinum-resistant ovarian carcinoma (Gietema et al., 1993a,b Pharmacokinetic analysis was performed in eight consecutive patients during the first course of lobaplatin 50 mg m-2. Blood samples were drawn on ice from the noninfused arm in heparinised glass tubes (Venoject, Omnilabo, Breda, The Netherlands) before infusion and at t =0 (just after end of infusion) and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 720 Figure 2 . The median survival of platinum-sensitive patients has not yet been reached, whereas the median survival of the platinum resistant patients was 7 months.
Toxicity
As expected from phase I studies, myelotoxicity was the major and dose-limiting toxicity of lobaplatin. In 11 patients the lobaplatin dose could be escalated after the first course, whereas in two patients the does had to be de-escalated. The haematological toxicity data are detailed in Table III Nwnber of patients 1 week. All patients recovered from haematological toxicity within 28 days after lobaplatin admiimstration. Seven patients required prophylactic platelet transfusions during grade 4 thrombocytopenia. There were no signs of clinical bleeding during thrombocytopenia. As anticipated from phase I studies with lobaplatin, we suspected a relation between thrombocytopenia and renal function. For 15 patients treated with 50 mg m-2 lobaplatin as first course, we observed (see Figure 3 ) a significant correlation between CRCL and percentage reduction in platelet count (r = -0.77; P<0.01). There were no episodes of neutropenic fever. Eleven patients developed symptomatic anaemia during lobaplatin treatment; this required red blood cell transfusions in six patients. In patients who received 4-6 courses lobaplatin (n = 10), there were signs of cumulative toxicity mainly concerning the number of platelets and erythrocytes.
Non-haematological toxicity was confined to mild nausea and vomiting despite the use of prophylactic 5-HT3 receptor antagonists in 14/22 patients (64% Figure 4 . Lobaplatin concentrations were corrected for difference in molecular weight in order to make comparisons with atomic TPt and FPt possible. In all patients levels were non-detectable from 12 h after infusion. Additional pharmacokinetic parameters are summarised in Table IV . An open two-compartment model resulted in the best fit for TPt, FPt and native lobaplatin. In Figure 5 , the free Pt fraction (FPt/TPt) is depicted for the period at which both species could be accurately measured (t = 240 min). This ratio is initially very high and decreases gradually, indicating low protein binding. The fraction lobaplatin/FPt is also shown in Figure 5 and reveals that free platinum is mainly present in the form of native lobaplatin. Elimination of lobaplatin is characterised by rapid urinary excretion, as shown in Figure 6 . Calculation of the renal platinum clearance based on measured urine samples amounted initially to a mean renal platinum clearance of 104 ± 30 ml min-' (the mean CRCL of these eight studied patients was 100 ± 12 ml min-').
We studied the possible relationship between CRCL and drug clearance. However, no correlation could be detected between CRCL and plasma clearance of either TPt, FPt or lobaplatin. Furthermore, no correlation was observed between the AUC of TPt, FPt, lobaplatin and percentage reduction in platelet count after the first course of lobaplatin respectively. Figwe 6 Cumulative urinary excretion of Pt (per cent of dose administered) (n = 8).
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Discusion
The current management of patients with ovarian cancer who have had recurrences after initial platinum-based chemotherapy is based on a consideration of results of the initial chemotherapy. Several studies have shown that the longer the period between completing the first-line and starting the second-line treatment, the higher the response rate will be of second-line platinum-based chemotherapy (Blackledge et al., 1989; Markman et al., 1991) . Such platinumbased therapy will yield response rates up to 40-60% for treatment-free intervals of more than 6 months (Kavanagh et al., 1989; Markman et al.. 1991) . In patients with clinically platinum-resistant disease (stable disease as best response or a partial response lasting less than 6 months) the response rate of second-line platinum-based therapy will be approximately 10% (Weiss et al.. 1991; Thigpen et al., 1993; Dobbs et al., 1994) . The poor response rates stimulated the development of drugs which show activity in platinum-resistant tumours. From phase I studies with new third-generation platinum analogue lobaplatin, activity in platinum-resistant ovarian cancer was suggested (Gietema et al., 1993a,b) . The present phase II study with lobaplatin in patients with residual or relapsed ovarian cancer after platinum-based chemotherapy shows an overall response rate of 24%. Most responses occurred in the patients who were considered potentially platinum sensitive. Only one of the 14 clinically platinum-resistant patients responded to lobaplatin treatment. In comparison with the second-line studies quoted above, the response rates of lobaplatin appear to be of the same magnitude. The results, especially for the platinumresistant group, are disappointing however, especially when compared with the phase I data of lobaplatin. In two phase I studies we observed three responses in nine relapsed ovarian cancer patients (Gietema et al., 1993a,b) . Two of these responding patients could be marked as platinum resistant. A difference with the current phase II study, however, is the schedule of administration. In our phase I studies lobaplatin was given in multiple doses (daily x 5) during one course or by 72 h continuous infusion. The current bolus infusion of lobaplatin once every 4 weeks is most convenient for the out-patient setting but might be less active in terms of drug exposure. Additional studies with other schedules evaluating dose intensity will be needed to resolve this issue.
The main adverse effect of lobaplatin concerned the bone marrow, with thrombocytopenia as dose-limiting toxicity. While the dose of lobaplatin was escalated in case of mild toxicity, most patients developed short-lived but profound grade 3 or 4 thrombocytopenia. As was expected from the phase I studies, the reduction in platelet counts was related to renal function. Leucopenia was mild, with no signs of neutropenic fever. Symptomatic anaemia occurred in several patients treated with more than four courses of lobaplatin as a sign of cumulative toxicity. Of importance is the observation that during this study non-haematological toxicity was limited to mild nausea and vomiting. No signs of nephrotoxicity or neurotoxicity was observed. This toxicity profile makes lobaplatin a good candidate for dose-intensification strategies.
Pharmacokinetic analysis of lobaplatin measured as total and free platinum concentrations with AAS and native lobaplatin with an HPLC method revealed low protein binding and rapid urinary excretion. Free platinum is mainly present as intact lobaplatin. It can be stated that the pharmacokinetic profile of lobaplatin approximately resembles that of carboplatin (Harland et al., 1984; Gaver et al., 1988) . Plasma elimination data showed that the plasma clearance of lobaplatin exceeds the CRCL. suggesting that the platinum species are at least partially actively excreted into the urine. This is different from carboplatin, which has a platinum plasma clearance which is similar to the CRCL (Harland et al., 1984) . However, when renal platinum clearance was calculated, this appeared to be similar to CRCL, suggesting that there might be irreversible tissue binding of lobaplatin. Because the kidney is the main route of excretion and platelet toxicity is related to renal function, a relation between lobaplatin plasma clearance and CRCL and a correlation between lobaplatin AUC and reduction in platelet counts were expected, as have been previously described for carboplatin (Egorin et al., 1984; Calvert et al.. 1989) . Probably because of the small number of patients with only little variation in CRCL no significant pharmacodynamic relations could be detected.
In conclusion. lobaplatin showed anti-tumour activity as a second-line treatment in patients with relapsed ovarian cancer. Short-lived thrombocytopenia is the dose-limiting toxicity of lobaplatin and is related to CRCL. No renal function disturbances were observed during treatment with lobaplatin. Lobaplatin showed a relatively low protein binding, with most of unbound platinum present as native lobaplatin, and a rapid urinary excretion. Additional studies with lobaplatin also employing other schedules are warranted to further define its activity in platinum-resistant ovarian cancer and other cancers.
